Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What CAGR And Valuation Are Anticipated For The Inhaler Corticosteroid Device Market?
The market size for inhaler corticosteroid devices has seen significant expansion in the past few years. The market is projected to extend from $15.75 billion in 2024 to become a $16.83 billion market in 2025. This represents a compound annual growth rate (CAGR) of 6.9%. This upward trend during the historic period has been fuelled by factors such as increased spending on healthcare, a growing elderly population, favorable government initiatives, ongoing research and development activities, and a higher level of disposable income.
Expectations are high for a substantial expansion in the inhaler corticosteroid device market size in the coming years. Predictions show a rise to $21.77 billion in 2029, with a compound annual growth rate (CAGR) of 6.6%. This progression during the forecast period is likely due to the increasing prevalence of respiratory diseases, heightened consciousness concerning respiratory health, substantial investments in respiratory technologies, growing emphasis on health consciousness, and an uptick in smoking addiction rates. Notable trends throughout the forecast period encompass the introduction of smart technologies, the creation of combination therapies, digital inhaler devices yielding real-time data, advancements in inhaler technologies, and the application of data analytics in inhaler devices.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25794&type=smp
What Core Drivers Are Expected To Influence The Inhaler Corticosteroid Device Market?
The rise in respiratory illnesses is anticipated to boost the inhaler corticosteroid device market’s expansion. Respiratory illnesses include various conditions impacting the lungs and airways, affecting individuals’ ability to breathe effectively. Greater air pollution is leading to an increased occurrence of these diseases, as people are exposed to harmful particles that harm lung tissue and provoke chronic illnesses such as asthma and bronchitis. Inhaler corticosteroid devices, which deliver anti-inflammatory medication to the lungs directly, are utilized in the treatment of these respiratory diseases, assisting in reducing inflammation and enhancing breathing. For instance, in June 2025, the UK’s Office for Health Improvement and Disparities reported 854,922 emergency hospital admissions in England for respiratory diseases in the financial year ended 2024. This equates to a rate of 1,428 (ranging from 1,424 to 1,432) per 100,000 population, which signifies a 7% increase from the previous year. Consequently, the rising occurrence of respiratory illnesses is fueling the inhaler corticosteroid device market’s growth.
What Are The Main Segment Classifications In The Inhaler Corticosteroid Device Market?
The inhaler corticosteroid device market covered in this report is segmented –
1) By Product Type: Metered-Dose Inhalers, Dry Powder Inhalers, Soft Mist Inhalers
2) By Formulation Type: Fluticasone Propionate, Budesonide, Beclomethasone, Mometasone Furoate
3) By Distribution Channel: Online Pharmacies, Retail Pharmacies, Direct Sales, Hospital Pharmacies
4) By Application: Asthma, Chronic Obstructive Pulmonary Disease (COPD), Other Applications
5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users
Subsegments:
1) By Metered-Dose Inhalers: Conventional Metered-Dose Inhalers, Breath-Actuated Metered-Dose Inhalers, Spacer-Integrated Metered-Dose Inhalers
2) By Dry Powder Inhalers: Single-Dose Dry Powder Inhalers, Multi-Dose Dry Powder Inhalers, Reservoir Dry Powder Inhalers
3) By Soft Mist Inhalers: Manual Soft Mist Inhalers, Battery-Operated Soft Mist Inhalers
How Are Industry Trends Steering The Expansion Of The Inhaler Corticosteroid Device Market?
Leading organizations in the inhaler corticosteroid device market have their objectives set on the development of inventive solutions, specifically, rescue inhalers that integrate both albuterol and budesonide. This combination seeks to upscale the efficacy of treatments and offers dual-action therapy in one device, enhancing convenience for patients. A rescue inhaler that merges albuterol and budesonide is one which delivers both a bronchodilator (albuterol) for immediate airway opening, and a corticosteroid (budesonide) to mitigate inflammation, all in one. This combination brings forth quick relief of symptoms and long-lasting asthma control. A typical illustration of this was in January 2024 when AstraZeneca PLC, a British pharmaceutical company, launched AIRSUPRA, the only rescue inhaler integrating albuterol and budesonide that has gained FDA approval for adults with asthma. This inhaler is designed for immediate use to alleviate acute bronchoconstriction symptoms and minimize inflammation of the airways, thus reducing the occurrence of severe asthma attacks. The innovative aspect of AIRSUPRA lies in its combination of a quick-acting beta2-agonist (albuterol) with an inhaled corticosteroid (budesonide) in one inhaler. Its approval was backed by clinical trials showing that it was superior to albuterol alone in preventing asthma flare-ups.
Which Companies Are Contributing Significantly To The Inhaler Corticosteroid Device Market Growth?
Major companies operating in the inhaler corticosteroid device market are AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Teijin Pharma Limited, Sun Pharmaceutical Industries Limited, Aurobindo Pharma Limited, Chiesi Farmaceutici S.p.A., Cipla Limited, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Mundipharma International Limited, Lupin Limited, Zydus Lifesciences Limited, Recipharm AB, Glenmark Pharmaceuticals Limited, Orion Corporation, Beximco Pharmaceuticals Limited, PARI Medical Holding GmbH, Kos Pharmaceuticals Inc.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/inhaler-corticosteroid-device-global-market-report
Which Region Holds The Greatest Opportunity For Inhaler Corticosteroid Device Market Expansion?
North America was the largest region in the inhaler corticosteroid device market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhaler corticosteroid device market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25794&type=smp
Browse Through More Reports Similar to the Global Inhaler Corticosteroid Device Market 2025, By The Business Research Company
Veterinary Infectious Disease Diagnostics Global Market Report 2025
Clinical Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/clinical-diagnostics-global-market-report
Viral Diagnostic Test Kits Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/viral-diagnostic-test-kits-global-market-report
About The Business Research Company:
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model